Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8165902 | 0.79 | KDM4E (0.46) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL13346383 | 0.76 | KDM4E (0.47) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL13701829 | 0.75 | EPHX2 (0.39) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL15466780 | 0.75 | KDM4E (0.46) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL16704799 | 0.75 | KDM4E (0.42) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL8077229 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL13995759 | 0.74 | KDM4E (0.39) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL14159942 | 0.74 | EPHX2 (0.41) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL24841918 | 0.73 | KDM4E (0.41) | KDM4EALDH1A1MEN1KMT2AHTT | |
| SCHEMBL7264172 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6991741-B2 | Controlled room temperature synthesis of magnetic metal oxide nanoclusters within a diblock copolymer matrix | UNIVERSITY OF MARYLAND (US) | 2006-01-31 | — | — | US | claimed |
| US-20040238783-A1 | Controlled room temperature synthesis of magnetic metal oxide nanoclusters within a diblock copolymer matrix | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2004-12-02 | — | — | US | claimed |
| US-20150232616-A1 | HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS | INTEZYNE TECHNOLOGIES, INC. | 2015-08-20 | — | — | US | disclosed |
| US-8779008-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779008-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | INTEZYNE TECHNOLOGIES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8426477-B1 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8268936-B2 | Synthesis of hybrid block copolymers and uses thereof | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8263665-B2 | Polymeric micelles for drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263663-B2 | Azide functionalized peptide targeting groups | INTEZYNE TECHNOLOGIES, INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-7618944-B2 | Encapsulating in micelle which is a block copolymer containing hydrophilic and hydrophobic blocks | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7601796-B2 | polyamideether copolymer has a hydrophilic polyethylene glycol and a hydrophobic polyamino acid blocks; modified polyethylene glycol homopolymer; forming conjugate polymer drug; resin peptides; use in pharmaceutically acceptable compositions | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | INTEZYNE TECHNOLOGIES, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | INTEZYNE TECHNOLOGIES, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
| US-6991741-B2 | Controlled room temperature synthesis of magnetic metal oxide nanoclusters within a diblock copolymer matrix | UNIVERSITY OF MARYLAND (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040238783-A1 | Controlled room temperature synthesis of magnetic metal oxide nanoclusters within a diblock copolymer matrix | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2004-12-02 | — | — | US | disclosed |
| US-5603985-A | Block copolymer adhesion promoters via ring-opening metathesis polymerization | ENERGY, UNITED STATES DEPARTMENT OF | 1997-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080035243-A1 | Covalent modification of metal surfaces | ITGAL, ITGA1, ITGA5 | KDM4E 1193/4885ALDH1A1 933/4885MEN1 3171/4885 |
| US-20080274965-A1 | ENCAPSULATED AMYLOID-BETA PEPTIDES | IAPP, APP, TTR | KDM4E 4852/4885ALDH1A1 4688/4885MEN1 227/4885 |
| US-20130195987-A1 | POLYMERIC MICELLES FOR DRUG DELIVERY | ABCB4, CLTB, CD47 | KDM4E 4278/4885ALDH1A1 4414/4885MEN1 920/4885 |
| US-20090092554-A1 | ENCAPSULATED CONTRAST AGENTS | LIPA, LPXN, CD47 | KDM4E 4151/4885ALDH1A1 3588/4885MEN1 161/4885 |
| US-20080274173-A1 | Copolymer of crosslinkable or crosslinked poly(amino acid block), and a hydrophobic D,L-mixed poly(amino acid) block; an inner core, crosslinked outer core, a hydrophilic shell; improved in vivo circulation time; drug delivery | CLTB, SLC1A5, CLTA | KDM4E 2218/4885ALDH1A1 3966/4885MEN1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.